Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia

James R. Marshall, Wael Sakr, David Wood, Donna Berry, Catherine Tangen, Felicia Parker, Ian Thompson, Scott M. Lippman, Ronald Lieberman, David S Alberts, David Jarrard, Charles Coltman, Peter Greenwald, Lori Minasian, E. David Crawford

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

High-grade prostatic intraepithelial neoplasia (HGFIN) is generally regarded as a premalignant lesion that progresses toward prostate cancer. In light of the significant sequelae of prostate cancer treatment, prevention is desirable, and men with HGPIN would be suitable, high-risk subjects. There is in vitro, in vivo, epidemiologic, and human experimental evidence that selenium supplementation may protect against prostate cancer. This article introduces the rationale for, and progress to date, of a double-blind, randomized, placebo-controlled trial of selenium supplementation (200 μg/d in the form of selenomethionine), to prevent the development of prostate cancer among men with HGPIN. The trial, Southwest Oncology Group Protocol 9917, funded by a National Cancer Institute program supporting pivotal prevention trials has registered 537 patients and has randomized >380 to date. Subject accrual is expected to be completed by the fall of 2006, with trial completion in 2009.

Original languageEnglish (US)
Pages (from-to)1479-1484
Number of pages6
JournalCancer Epidemiology Biomarkers and Prevention
Volume15
Issue number8
DOIs
StatePublished - Aug 2006

Fingerprint

Prostatic Intraepithelial Neoplasia
Selenium
Prostatic Neoplasms
Selenomethionine
National Cancer Institute (U.S.)
Randomized Controlled Trials
Placebos

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia. / Marshall, James R.; Sakr, Wael; Wood, David; Berry, Donna; Tangen, Catherine; Parker, Felicia; Thompson, Ian; Lippman, Scott M.; Lieberman, Ronald; Alberts, David S; Jarrard, David; Coltman, Charles; Greenwald, Peter; Minasian, Lori; Crawford, E. David.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 15, No. 8, 08.2006, p. 1479-1484.

Research output: Contribution to journalArticle

Marshall, JR, Sakr, W, Wood, D, Berry, D, Tangen, C, Parker, F, Thompson, I, Lippman, SM, Lieberman, R, Alberts, DS, Jarrard, D, Coltman, C, Greenwald, P, Minasian, L & Crawford, ED 2006, 'Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia', Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 8, pp. 1479-1484. https://doi.org/10.1158/1055-9965.EPI-05-0585
Marshall, James R. ; Sakr, Wael ; Wood, David ; Berry, Donna ; Tangen, Catherine ; Parker, Felicia ; Thompson, Ian ; Lippman, Scott M. ; Lieberman, Ronald ; Alberts, David S ; Jarrard, David ; Coltman, Charles ; Greenwald, Peter ; Minasian, Lori ; Crawford, E. David. / Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia. In: Cancer Epidemiology Biomarkers and Prevention. 2006 ; Vol. 15, No. 8. pp. 1479-1484.
@article{0ccdef8f0777452ea9f6434c9dd5e7be,
title = "Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia",
abstract = "High-grade prostatic intraepithelial neoplasia (HGFIN) is generally regarded as a premalignant lesion that progresses toward prostate cancer. In light of the significant sequelae of prostate cancer treatment, prevention is desirable, and men with HGPIN would be suitable, high-risk subjects. There is in vitro, in vivo, epidemiologic, and human experimental evidence that selenium supplementation may protect against prostate cancer. This article introduces the rationale for, and progress to date, of a double-blind, randomized, placebo-controlled trial of selenium supplementation (200 μg/d in the form of selenomethionine), to prevent the development of prostate cancer among men with HGPIN. The trial, Southwest Oncology Group Protocol 9917, funded by a National Cancer Institute program supporting pivotal prevention trials has registered 537 patients and has randomized >380 to date. Subject accrual is expected to be completed by the fall of 2006, with trial completion in 2009.",
author = "Marshall, {James R.} and Wael Sakr and David Wood and Donna Berry and Catherine Tangen and Felicia Parker and Ian Thompson and Lippman, {Scott M.} and Ronald Lieberman and Alberts, {David S} and David Jarrard and Charles Coltman and Peter Greenwald and Lori Minasian and Crawford, {E. David}",
year = "2006",
month = "8",
doi = "10.1158/1055-9965.EPI-05-0585",
language = "English (US)",
volume = "15",
pages = "1479--1484",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia

AU - Marshall, James R.

AU - Sakr, Wael

AU - Wood, David

AU - Berry, Donna

AU - Tangen, Catherine

AU - Parker, Felicia

AU - Thompson, Ian

AU - Lippman, Scott M.

AU - Lieberman, Ronald

AU - Alberts, David S

AU - Jarrard, David

AU - Coltman, Charles

AU - Greenwald, Peter

AU - Minasian, Lori

AU - Crawford, E. David

PY - 2006/8

Y1 - 2006/8

N2 - High-grade prostatic intraepithelial neoplasia (HGFIN) is generally regarded as a premalignant lesion that progresses toward prostate cancer. In light of the significant sequelae of prostate cancer treatment, prevention is desirable, and men with HGPIN would be suitable, high-risk subjects. There is in vitro, in vivo, epidemiologic, and human experimental evidence that selenium supplementation may protect against prostate cancer. This article introduces the rationale for, and progress to date, of a double-blind, randomized, placebo-controlled trial of selenium supplementation (200 μg/d in the form of selenomethionine), to prevent the development of prostate cancer among men with HGPIN. The trial, Southwest Oncology Group Protocol 9917, funded by a National Cancer Institute program supporting pivotal prevention trials has registered 537 patients and has randomized >380 to date. Subject accrual is expected to be completed by the fall of 2006, with trial completion in 2009.

AB - High-grade prostatic intraepithelial neoplasia (HGFIN) is generally regarded as a premalignant lesion that progresses toward prostate cancer. In light of the significant sequelae of prostate cancer treatment, prevention is desirable, and men with HGPIN would be suitable, high-risk subjects. There is in vitro, in vivo, epidemiologic, and human experimental evidence that selenium supplementation may protect against prostate cancer. This article introduces the rationale for, and progress to date, of a double-blind, randomized, placebo-controlled trial of selenium supplementation (200 μg/d in the form of selenomethionine), to prevent the development of prostate cancer among men with HGPIN. The trial, Southwest Oncology Group Protocol 9917, funded by a National Cancer Institute program supporting pivotal prevention trials has registered 537 patients and has randomized >380 to date. Subject accrual is expected to be completed by the fall of 2006, with trial completion in 2009.

UR - http://www.scopus.com/inward/record.url?scp=33748056428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748056428&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-05-0585

DO - 10.1158/1055-9965.EPI-05-0585

M3 - Article

VL - 15

SP - 1479

EP - 1484

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 8

ER -